Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Gandara

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
The Cancer Journal From Scientific American|August 10, 1999
Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trialP J Hesketh, J J Crowley, H A Burris, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2001
Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancerC R Thomas, D J Giroux, L M Janaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trialK Kelly, J Crowley, P A Bunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2007
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinibF R Hirsch, M Varella-Garcia, F Cappuzzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollmentP N Lara, R Higdon, N Lim, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2001
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium TrialP N Lara, D R Gandara, J Longmate, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2013
KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapiesM K H Maus, P P Grimminger, P C Mack, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2018
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK studyJ von Pawel, R Bordoni, M Satouchi, et al.
British Journal of Cancer|October 29, 2014
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumorsM Koczywas, P H Frankel, T W Synold, et al.
Journal of the National Cancer Institute|April 20, 2001
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancerS M Lippman, J J Lee, D D Karp, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
The Cancer Journal From Scientific American|August 10, 1999
Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trialP J Hesketh, J J Crowley, H A Burris, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2001
Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancerC R Thomas, D J Giroux, L M Janaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trialK Kelly, J Crowley, P A Bunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2007
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinibF R Hirsch, M Varella-Garcia, F Cappuzzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollmentP N Lara, R Higdon, N Lim, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2001
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium TrialP N Lara, D R Gandara, J Longmate, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2013
KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapiesM K H Maus, P P Grimminger, P C Mack, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2018
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK studyJ von Pawel, R Bordoni, M Satouchi, et al.
British Journal of Cancer|October 29, 2014
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumorsM Koczywas, P H Frankel, T W Synold, et al.
Journal of the National Cancer Institute|April 20, 2001
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancerS M Lippman, J J Lee, D D Karp, et al.
Pageof 9